刘伟为，男，2020年博士毕业于慕尼黑大学，师从Gerhard Winter教授进行生物制药技术的研究。曾先后任职于药明康德、慕尼黑大学、臻乐医药等， 长期从事核酸药物与纳米药物研究和开发。先后主持过预防性mRNA疫苗、蛋白药物半固体制剂与冻干工艺、蛋白药物半固体制剂皮下缓控释模拟模型、以及用于核酸药物皮内给药的微针预灌封注射器等项目的研究与开发工作。主要研究发表在Biomaterials，Advanced Functional Materials，Langmuir和 Chinese Journal of Chemistry等；此外，作为第1、2 发明人共申请国内外专利14项（含优先权），其中已授权专利3项。

核酸药物与纳米药物递送、生物大分子药物制剂、先进制剂工艺开发与评价

[1]Xiao-Jiao Du#, Ji-Long Wang#, Wei-Wei Liu#authors contributed equally, Jin-Xian Yang, Chun-Yang Sun, Rong Sun, Hong-Jun Li, Song Shen, Ying-Li Luo, Yan-Hua Zhu, Xiao-Dong Ye*, Xian-Zhu Yang, Jun Wang*, Regulating the Surface Polyethylene glycol Density of Polymeric Nanoparticles and Evaluating its Role in Drug Delivery in vivo, Biomaterials, 2015, DOI: 10.1016/j.biomaterials.2015.07.048

[2]W. W. Liu, Y. C. Wang, Y. Li, F. Wang, X. Z. Yang, T. M. Sun, J. Z. Du and J. Wang*, Multiresponsive Polymer Assemblies Achieved by A Subtle Chain Terminal Modification for Drug Delivery. Chinese Journal of Chemistry, 2013, DOI: 10.1002/cjoc.201300736

[3] Xiaohan Zhang, Petr Chytil, Tomá? Etrych, Weiwei Liu, Leticia Rodrigues, Gerhard Winter, Sergey K. Filippov, and Christine M. Papadakis,. Binding of HSA to Macromolecular pHPMA Based Nanoparticles for Drug Delivery: An Investigation Using Fluorescence Methods. Langmuir， 2018, 34, 27, 7998–8006

[4] Shi Liang#, Xian-Zhu Yang*, Xiao-Jiao Du, Hong-Xia Wang, Hong-Jun Li, Wei-Wei Liu, Jun Wang*, Erwei Song*, Optimizing the Size of Micellar Nanoparticles for Efficient siRNA Delivery, Advanced Functional Materials, DOI: 10.1002/adfm.201501548

作为第一、二发明人，已提交国内外专利14项、已授权3项

[1]  微针注射mRNA疫苗及其应用
        202210994917.2  20230616已授权

[2]微针注射mRNA编码双特异性抗体药物的试剂、方法和应用
      202210897045.8  20230808已授权

[3]一种水痘-带状疱疹病毒 mRNA 疫苗及其应用
      202310117947.X  20231201已授权